AnGes, Inc. (4563.T)
JPY 78.0
(5.41%)
JPY 78.0
(5.41%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 28.89 Billion JPY | -25.57% |
| 2022 | 38.82 Billion JPY | -14.6% |
| 2021 | 45.45 Billion JPY | 18.51% |
| 2020 | 38.35 Billion JPY | 206.23% |
| 2019 | 12.52 Billion JPY | 55.57% |
| 2018 | 8.05 Billion JPY | 103.11% |
| 2017 | 3.96 Billion JPY | -12.68% |
| 2016 | 4.53 Billion JPY | -4.48% |
| 2015 | 4.75 Billion JPY | -41.93% |
| 2014 | 8.18 Billion JPY | 109.61% |
| 2013 | 3.9 Billion JPY | 72.73% |
| 2012 | 2.26 Billion JPY | -41.89% |
| 2011 | 3.88 Billion JPY | -22.28% |
| 2010 | 5 Billion JPY | -30.13% |
| 2009 | 7.16 Billion JPY | -26.0% |
| 2008 | 9.67 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 27.67 Billion JPY | -1.26% |
| 2024 Q1 | 28.02 Billion JPY | -2.99% |
| 2023 Q1 | 37.19 Billion JPY | -4.19% |
| 2023 Q2 | 36.79 Billion JPY | -1.08% |
| 2023 FY | 28.89 Billion JPY | -25.57% |
| 2023 Q4 | 28.89 Billion JPY | -17.1% |
| 2023 Q3 | 34.85 Billion JPY | -5.27% |
| 2022 Q3 | 39.89 Billion JPY | -6.33% |
| 2022 Q2 | 42.59 Billion JPY | -3.33% |
| 2022 Q1 | 44.06 Billion JPY | -3.07% |
| 2022 FY | 38.82 Billion JPY | -14.6% |
| 2022 Q4 | 38.82 Billion JPY | -2.69% |
| 2021 Q2 | 51.75 Billion JPY | 22.47% |
| 2021 Q3 | 47.73 Billion JPY | -7.77% |
| 2021 Q4 | 45.45 Billion JPY | -4.78% |
| 2021 FY | 45.45 Billion JPY | 18.51% |
| 2021 Q1 | 42.26 Billion JPY | 10.19% |
| 2020 FY | 38.35 Billion JPY | 206.23% |
| 2020 Q3 | 21.36 Billion JPY | -3.31% |
| 2020 Q2 | 22.09 Billion JPY | 51.36% |
| 2020 Q4 | 38.35 Billion JPY | 79.49% |
| 2020 Q1 | 14.59 Billion JPY | 16.57% |
| 2019 Q4 | 12.52 Billion JPY | -6.25% |
| 2019 FY | 12.52 Billion JPY | 55.57% |
| 2019 Q1 | 11.93 Billion JPY | 48.25% |
| 2019 Q2 | 13.92 Billion JPY | 16.65% |
| 2019 Q3 | 13.36 Billion JPY | -4.04% |
| 2018 Q3 | 6.11 Billion JPY | 20.63% |
| 2018 Q1 | 4.01 Billion JPY | 1.25% |
| 2018 Q2 | 5.06 Billion JPY | 26.27% |
| 2018 FY | 8.05 Billion JPY | 103.11% |
| 2018 Q4 | 8.05 Billion JPY | 31.7% |
| 2017 Q2 | 4.73 Billion JPY | 23.06% |
| 2017 FY | 3.96 Billion JPY | -12.68% |
| 2017 Q4 | 3.96 Billion JPY | -11.59% |
| 2017 Q3 | 4.48 Billion JPY | -5.4% |
| 2017 Q1 | 3.85 Billion JPY | -15.17% |
| 2016 Q3 | 5.35 Billion JPY | -0.87% |
| 2016 Q1 | 3.76 Billion JPY | -20.72% |
| 2016 FY | 4.53 Billion JPY | -4.48% |
| 2016 Q4 | 4.53 Billion JPY | -15.17% |
| 2016 Q2 | 5.39 Billion JPY | 43.28% |
| 2015 Q1 | 7.28 Billion JPY | -10.95% |
| 2015 FY | 4.75 Billion JPY | -41.93% |
| 2015 Q3 | 6.16 Billion JPY | -15.62% |
| 2015 Q2 | 7.31 Billion JPY | 0.34% |
| 2015 Q4 | 4.75 Billion JPY | -22.98% |
| 2014 Q1 | 3.43 Billion JPY | -11.93% |
| 2014 Q4 | 8.18 Billion JPY | -5.49% |
| 2014 Q3 | 8.65 Billion JPY | 143.53% |
| 2014 Q2 | 3.55 Billion JPY | 3.42% |
| 2014 FY | 8.18 Billion JPY | 109.61% |
| 2013 Q2 | 4.46 Billion JPY | 23.82% |
| 2013 Q3 | 4.53 Billion JPY | 1.48% |
| 2013 Q4 | 3.9 Billion JPY | -13.83% |
| 2013 FY | 3.9 Billion JPY | 72.73% |
| 2013 Q1 | 3.6 Billion JPY | 59.53% |
| 2012 Q4 | 2.26 Billion JPY | -21.23% |
| 2012 Q3 | 2.86 Billion JPY | -5.37% |
| 2012 Q2 | 3.03 Billion JPY | -8.74% |
| 2012 Q1 | 3.32 Billion JPY | -14.58% |
| 2012 FY | 2.26 Billion JPY | -41.89% |
| 2011 FY | 3.88 Billion JPY | -22.28% |
| 2011 Q3 | 4.11 Billion JPY | -18.3% |
| 2011 Q2 | 5.03 Billion JPY | -2.03% |
| 2011 Q4 | 3.88 Billion JPY | -5.45% |
| 2011 Q1 | 5.13 Billion JPY | 2.69% |
| 2010 Q2 | 6.35 Billion JPY | -7.26% |
| 2010 Q1 | 6.85 Billion JPY | -4.26% |
| 2010 FY | 5 Billion JPY | -30.13% |
| 2010 Q3 | 5.61 Billion JPY | -11.77% |
| 2010 Q4 | 5 Billion JPY | -10.8% |
| 2009 Q3 | 7.89 Billion JPY | -4.74% |
| 2009 FY | 7.16 Billion JPY | -26.0% |
| 2009 Q2 | 8.28 Billion JPY | -10.24% |
| 2009 Q1 | 9.23 Billion JPY | 0.0% |
| 2009 Q4 | 7.16 Billion JPY | -9.3% |
| 2008 FY | 9.67 Billion JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | -338.475% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -2285.002% |
| GNI Group Ltd. | 62.39 Billion JPY | 53.694% |
| Linical Co., Ltd. | 18.53 Billion JPY | -55.84% |
| Trans Genic Inc. | 9.81 Billion JPY | -194.491% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -412.811% |
| Soiken Holdings Inc. | 6.94 Billion JPY | -315.951% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | -396.748% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -3231.416% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 81.62% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -1685.052% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -469.729% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -564.213% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -1087.598% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -1117.363% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | -316.903% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -1549.631% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -468.13% |
| PeptiDream Inc. | 67.12 Billion JPY | 56.958% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -1315.886% |
| Ribomic Inc. | 3.54 Billion JPY | -714.504% |
| SanBio Company Limited | 5.04 Billion JPY | -472.437% |
| Healios K.K. | 15.15 Billion JPY | -90.647% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -2248.496% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -857.975% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -1859.939% |
| StemRIM | 9.08 Billion JPY | -218.2% |
| CellSource Co., Ltd. | 6.87 Billion JPY | -319.966% |
| FunPep Company Limited | 2.49 Billion JPY | -1059.815% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -1003.334% |
| Stella Pharma Corporation | 3.82 Billion JPY | -656.226% |
| TMS Co., Ltd. | 3.55 Billion JPY | -712.786% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -399.962% |
| Cuorips Inc. | 6.18 Billion JPY | -367.159% |
| K Pharma,Inc. | 3.31 Billion JPY | -771.858% |
| Takara Bio Inc. | 123.2 Billion JPY | 76.55% |
| ReproCELL Incorporated | 9.05 Billion JPY | -219.162% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -964.056% |
| StemCell Institute Inc. | 6.54 Billion JPY | -341.574% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | -313.414% |
| CellSeed Inc. | 2.46 Billion JPY | -1071.746% |